Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial

[1]  Chien-Ning Hsu,et al.  Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study , 2021, Cardiovascular Diabetology.

[2]  C. Cannon,et al.  Ertugliflozin and Slope of Chronic eGFR , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[3]  C. Cannon,et al.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial , 2021, Diabetologia.

[4]  H. Heerspink,et al.  Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. , 2021, Kidney international.

[5]  C. Cannon,et al.  Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV. , 2020, Circulation.

[6]  C. Cannon,et al.  Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease , 2020, Circulation.

[7]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[8]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[9]  B. Zinman,et al.  Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial , 2020, Diabetes, obesity & metabolism.

[10]  D. Gilbertson,et al.  Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study , 2019, BMC Endocrine Disorders.

[11]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[12]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[13]  V. Klimontov,et al.  Albuminuric and non-albuminuric patterns of chronic kidney disease in type 2 diabetes. , 2019, Diabetes & metabolic syndrome.

[14]  C. Cannon,et al.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.

[15]  C. Reid,et al.  Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  K. Mahaffey,et al.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.

[17]  M. Cooper,et al.  Cardiovascular Disease and Diabetic Kidney Disease. , 2018, Seminars in nephrology.

[18]  R. Nelson,et al.  The Global Epidemiology of Diabetes and Kidney Disease. , 2018, Advances in chronic kidney disease.

[19]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[20]  S. Marshall.  Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. , 2014, Advances in chronic kidney disease.

[21]  Yahong Peng,et al.  Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials , 2008 .

[22]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.